BioCentury | Apr 21, 2020
Product Development
April 20 Quick Takes: Top-line data for BMS, Idorsia and Ascendis; plus Otsuka-Esperion, Regeneron and more
BMS combo meets in Phase III for malignant pleural mesothelioma Bristol Myers Squibb Co. (NYSE:BMY) said top-line results from the Phase III CheckMate -743 trial showed a combination of anti-PD-1 mAb Opdivo nivolumab and anti-CTLA4...